ABBV · 10-Q · 2026Q2 · Full report

Guidance / Outlook

AbbVie Inc. · 2026-08-03 · Importance 31 · Surprise 42

AbbVie’s 2026 strategy emphasizes its diversified revenue base, international commercial infrastructure and continued investment in new product launches and established brands. Management plans to expand its pipeline in immunology, neuroscience, oncology and aesthetics, while pursuing new growth opportunities including obesity. AbbVie expects multiple regulatory submissions, approvals and key clinical-trial data readouts during the next 12 months, including transitions of multiple mid-stage programs into late-stage development.

Key facts

• Diluted earnings per share for the six months ended June 30, 2026: $2.42. source